Faes Farma : Good Q1 2022 results in line with expectations
>Good Q1 2022 results, in line with expectations - Total Q1 2022 revenues reached € 116m (+22% y-o-y and above the+16% sales growth registered in previous quarter), in line with expectations. By division, sales of traditional products in Spain posted positive albeit slight growth, below the previous quarter (+3% y-o-y in Q1 2022 vs +14% in Q4 2021), reflecting the fall in Bilaxten revenues (-31% y-o-y) due to the end of the patent. Sales in Portugal recovered growth t...Faes Farma is engaged in the health care research, manufacture and sale of prescription pharmaceuticals, over-the-counter pharmaceuticals and fine chemicals, URGO bandages and dressings and LAZLO cosmetics.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.